Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
Abstract
:1. Introduction
2. Dopamine Synthesis and Signaling
3. Dopamine and Cognition
4. Alterations of Monoamines System in Diabetes
4.1. Serotonergic System
4.2. Dopaminergic System
5. Glucotoxicity Role in Dopaminergic Dysfunction and Cognitive Impairment
6. Conclusions and Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. ADA Classification of Diabetes Mellitus; World Health Organization: Geneva, Switzerland, 2019; ISBN 978-92-4-151570-2. [Google Scholar]
- Harding, J.L.; Pavkov, M.E.; Magliano, D.J.; Shaw, J.E.; Gregg, E.W. Global trends in diabetes complications: A review of current evidence. Diabetologia 2019, 62, 3–16. [Google Scholar] [CrossRef] [Green Version]
- Reasner, C.A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J. Cardiovasc. Pharmacol. 2008, 52, 136–144. [Google Scholar] [CrossRef] [PubMed]
- Petersmann, A.; Müller-Wieland, D.; Müller, U.A.; Landgraf, R.; Nauck, M.; Freckmann, G.; Heinemann, L.; Schleicher, E. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes 2019, 127, S1–S7. [Google Scholar] [CrossRef] [Green Version]
- Miles, W.R.; Root, H.F. Psychologic tests applied to diabetic patients. Arch. Intern. Med. 1922, 30, 767–777. [Google Scholar] [CrossRef] [Green Version]
- Bispham, J.A.; Hughes, A.S.; Driscoll, K.A.; McAuliffe-Fogarty, A.H. Novel Challenges in Aging with Type 1 Diabetes. Curr. Diabetes Rep. 2020, 20, 15. [Google Scholar] [CrossRef] [PubMed]
- Perlmuter, L.C.; Hakami, M.K.; Hodgson-Harrington, C.; Ginsberg, J.; Katz, J.; Singer, D.E.; Nathan, D.M. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am. J. Med. 1984, 77, 1043–1048. [Google Scholar] [CrossRef]
- Biessels, G.J.; Staekenborg, S.; Brunner, E.; Brayne, C.; Scheltens, P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol. 2006, 5, 64–74. [Google Scholar] [CrossRef]
- Koekkoek, P.S.; Kappelle, L.J.; van den Berg, E.; Rutten, G.E.; Biessels, G.J. Cognitive function in patients with diabetes mellitus: Guidance for daily care. Lancet Neurol. 2015, 14, 329–340. [Google Scholar] [CrossRef]
- Biessels, G.J.; Deary, I.J.; Ryan, C.M. Cognition and diabetes: A lifespan perspective. Lancet Neurol. 2008, 7, 184–190. [Google Scholar] [CrossRef]
- Hughes, T.M.; Ryan, C.M.; Aizenstein, H.J.; Nunley, K.; Gianaros, P.J.; Miller, R.; Costacou, T.; Strotmeyer, E.S.; Orchard, T.J.; Rosano, C. Frontal gray matter atrophy in middle aged adults with type 1 diabetes is independent of cardiovascular risk factors and diabetes complications. J. Diabetes Complicat. 2013, 27, 558–564. [Google Scholar] [CrossRef] [Green Version]
- Roy, B.; Ehlert, L.; Mullur, R.; Freeby, M.J.; Woo, M.A.; Kumar, R.; Choi, S. Regional Brain Gray Matter Changes in Patients with Type 2 Diabetes Mellitus. Sci. Rep. 2020, 10, 9925. [Google Scholar] [CrossRef] [PubMed]
- Moran, C.; Phan, T.G.; Chen, J.; Blizzard, L.; Beare, R.; Venn, A.; Münch, G.; Wood, A.G.; Forbes, J.; Greenaway, T.M.; et al. Brain Atrophy in Type 2 Diabetes. Diabetes Care 2013, 36, 4036–4042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brands, A.M.; Biessels, G.J.; de Haan, E.H.; Kappelle, L.J.; Kessels, R.P. The effects of type 1 diabetes on cognitive performance: A meta-analysis. Diabetes Care 2005, 28, 726–735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shalimova, A.; Graff, B.; Gąsecki, D.; Wolf, J.; Sabisz, A.; Szurowska, E.; Jodzio, K.; Narkiewicz, K. Cognitive Dysfunction in Type 1 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 2019, 104, 2239–2249. [Google Scholar] [CrossRef]
- Northam, E.A.; Anderson, P.J.; Jacobs, R.; Hughes, M.; Warne, G.L.; Werther, G.A. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 2001, 24, 1541–1546. [Google Scholar] [CrossRef] [Green Version]
- Gaudieri, P.A.; Chen, R.; Greer, T.F.; Holmes, C.S. Cognitive function in children with type 1 diabetes: A meta-analysis. Diabetes Care 2008, 31, 1892–1897. [Google Scholar] [CrossRef] [Green Version]
- Ryan, C.M.; Geckle, M.O.; Orchard, T.J. Cognitive efficiency declines over time in adults with Type 1 diabetes: Effects of micro- and macrovascular complications. Diabetologia 2003, 46, 940–948. [Google Scholar] [CrossRef] [Green Version]
- Ott, A.; Stolk, R.P.; van Harskamp, F.; Pols, H.A.; Hofman, A.; Breteler, M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53, 1937–1942. [Google Scholar] [CrossRef]
- Shuba, N.; Karan. Assessment of the cognitive status in diabetes mellitus. J. Clin. Diagn. Res. 2012, 6, 1658–1662. [Google Scholar] [CrossRef]
- Yau, P.L.; Javier, D.C.; Ryan, C.M.; Tsui, W.H.; Ardekani, B.A.; Ten, S.; Convit, A. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 2010, 53, 2298–2306. [Google Scholar] [CrossRef] [Green Version]
- Roberts, R.O.; Knopman, D.S.; Przybelski, S.A.; Mielke, M.M.; Kantarci, K.; Preboske, G.M.; Senjem, M.L.; Pankratz, V.S.; Geda, Y.E.; Boeve, B.F.; et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 2014, 82, 1132–1141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeung, S.E.; Fischer, A.L.; Dixon, R.A. Exploring effects of type 2 diabetes on cognitive functioning in older adults. Neuropsychology 2009, 23, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Palta, P.; Schneider, A.L.; Biessels, G.J.; Touradji, P.; Hill-Briggs, F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: A meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J. Int. Neuropsychol. Soc. 2014, 20, 278–291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, J.; Strachan, M.W.; Reynolds, R.M.; Frier, B.M.; Deary, I.J.; Fowkes, F.G.; Lee, A.J.; McKnight, J.; Halpin, P.; Swa, K.; et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes 2010, 59, 2883–2889. [Google Scholar] [CrossRef] [Green Version]
- Barzilay, J.I.; Lovato, J.F.; Murray, A.M.; Williamson, J.; Ismail-Beigi, F.; Karl, D.; Papademetriou, V.; Launer, L.J. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clin. J. Am. Soc. Nephrol. 2013, 8, 1907–1914. [Google Scholar] [CrossRef] [PubMed]
- Umegaki, H.; Hayashi, T.; Nomura, H.; Yanagawa, M.; Nonogaki, Z.; Nakshima, H.; Kuzuya, M. Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly. Geriatr. Gerontol. Int. 2013, 13, 28–34. [Google Scholar] [CrossRef]
- Haroon, N.N.; Austin, P.C.; Shah, B.R.; Wu, J.; Gill, S.S.; Booth, G.L. Risk of dementia in seniors with newly diagnosed diabetes: A population-based study. Diabetes Care 2015, 38, 1868–1875. [Google Scholar] [CrossRef] [Green Version]
- Nelson, P.T.; Smith, C.D.; Abner, E.A.; Schmitt, F.A.; Scheff, S.W.; Davis, G.J.; Keller, J.N.; Jicha, G.A.; Davis, D.; Wang-Xia, W.; et al. Human cerebral neuropathology of type 2 diabetes mellitus. Biochim. Biophys. Acta 2009, 1792, 454–469. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Liu, L.; Lu, S.; Wang, D.; Liu, X.; Xie, L.; Wang, G. Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats. J. Endocrinol. Investig. 2011, 34, 26–31. [Google Scholar] [CrossRef]
- Kim, B.; Backus, C.; Oh, S.; Hayes, J.M.; Feldman, E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150, 5294–5301. [Google Scholar] [CrossRef] [Green Version]
- Mimenza-Alvarado, A.J.; Jiménez-Castillo, G.A.; Yeverino-Castro, S.G.; Barragán-Berlanga, A.J.; Pérez-Zepeda, M.U.; Ávila-Funes, J.A.; Aguilar-Navarro, S.G. Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: The Mexican Health and Aging Study. BMC Geriatr. 2020, 20, 424. [Google Scholar] [CrossRef]
- Cheng, H.; Gang, X.; Liu, Y.; Wang, G.; Zhao, X.; Wang, G. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am. J. Physiol. Endocrinol. Metab. 2020, 318, E750–E764. [Google Scholar] [CrossRef] [PubMed]
- Nagatsu, T.; Nakashima, A.; Ichinose, H.; Kobayashi, K. Human tyrosine hydroxylase in Parkinson’s disease and in related disorders. J. Neural Transm. 2019, 126, 397–409. [Google Scholar] [CrossRef] [PubMed]
- Silm, K.; Yang, J.; Marcott, P.F.; Asensio, C.S.; Eriksen, J.; Guthrie, D.A.; Newman, A.H.; Ford, C.P.; Edwards, R.H. Synaptic Vesicle Recycling Pathway Determines Neurotransmitter Content and Release Properties. Neuron 2019, 102, 786–800.e5. [Google Scholar] [CrossRef] [PubMed]
- Ito, H.; Kodaka, F.; Takahashi, H.; Takano, H.; Arakawa, R.; Shimada, H.; Suhara, T. Relation between Presynaptic and Postsynaptic Dopaminergic Functions Measured by Positron Emission Tomography: Implication of Dopaminergic Tone. J. Neurosci. 2011, 31, 7886–7890. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lévesque, D.; Diaz, J.; Pilon, C.; Martres, M.P.; Giros, B.; Souil, E.; Schott, D.; Morgat, J.L.; Schwartz, J.C.; Sokoloff, P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 1992, 89, 8155–8159. [Google Scholar] [CrossRef] [Green Version]
- Gardner, B.; Hall, D.A.; Strange, P.G. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol. 1996, 118, 1544–1550. [Google Scholar] [CrossRef]
- Gardner, B.; Strange, P.G. Agonist action at D2 (long) dopamine receptors: Ligand binding and functional assays. Br. J. Pharmacol. 1997, 124, 978–984. [Google Scholar] [CrossRef] [Green Version]
- Floresco, S.B.; West, A.R.; Ash, B.; Moore, H.; Grace, A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat. Neurosci. 2003, 6, 968–973. [Google Scholar] [CrossRef]
- Fagan, R.R.; Kearney, P.J.; Melikian, H.E. In Situ Regulated Dopamine Transporter Trafficking: There’s No Place Like Home. Neurochem. Res. 2020, 45, 1335–1343. [Google Scholar] [CrossRef]
- Kaur, S.; Singh, S.; Jaiswal, G.; Kumar, S.; Hourani, W.; Gorain, B.; Kumar, P. Pharmacology of Dopamine and Its Receptors. In Frontiers in Pharmacology of Neurotransmitters; Springer: Singapore, 2020. [Google Scholar] [CrossRef]
- Pelton, E.W., 2nd; Kimelberg, H.K.; Shipherd, S.V.; Bourke, R.S. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. Life Sci. 1981, 28, 1655–1663. [Google Scholar] [CrossRef]
- Chen, J.; Song, J.; Yuan, P.; Tian, Q.; Ji, Y.; Ren-Patterson, R.; Liu, G.; Sei, Y.; Weinberger, D.R. Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: Implications for drug development. J. Biol. Chem. 2011, 286, 34752–34760. [Google Scholar] [CrossRef] [Green Version]
- Klein, M.O.; Battagello, D.S.; Cardoso, A.R.; Hauser, D.N.; Bittencourt, J.C.; Correa, R.G. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell. Mol. Neurobiol. 2019, 39, 31–59. [Google Scholar] [CrossRef] [PubMed]
- Beaulieu, J.M.; Espinoza, S.; Gainetdinov, R.R. Dopamine receptors IUPHAR Review 13. Br. J. Pharmacol. 2015, 172, 1–23. [Google Scholar] [CrossRef] [Green Version]
- Beaulieu, J.M.; Gainetdinov, R.R. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacol. Rev. 2011, 63, 182–217. [Google Scholar] [CrossRef] [Green Version]
- Baik, J.H. Dopamine signaling in reward-related behaviors. Front. Neural Circuits 2013, 7, 152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, A.I.; Todd, R.D.; Harmon, S.; O’Malley, K.L. Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc. Natl. Acad. Sci. USA 1992, 89, 12093–12097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kebabian, J.W. Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitive adenylyl cyclase. Life Sci. 1978, 23, 479–483. [Google Scholar] [CrossRef]
- Cantrell, A.R.; Smith, R.D.; Goldin, A.L.; Scheuer, T.; Catterall, W.A. Dopaminergic modulation of sodium current in hippocampal neurons via cAMP-dependent phosphorylation of specific sites in the sodium channel alpha subunit. J. Neurosci. 1997, 17, 7330–7338. [Google Scholar] [CrossRef]
- Felder, C.C.; Jose, P.A.; Axelrod, J. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J. Pharmacol. Exp. Ther. 1989, 248, 171–175. [Google Scholar]
- Ugi, S.; Imamura, T.; Maegawa, H.; Egawa, K.; Yoshizaki, T.; Shi, K.; Obata, T.; Ebina, Y.; Kashiwagi, A.; Olefsky, J.M. Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell. Biol. 2004, 24, 8778–8789. [Google Scholar] [CrossRef] [Green Version]
- Laporte, S.A.; Miller, W.E.; Kim, K.M.; Caron, M.G. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: Identification of a beta-arrestin binging site in beta 2-adaptin. J. Biol. Chem. 2002, 277, 9247–9254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernheimer, H.; Hornykiewicz, O. Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism. Klin. Wochenschr. 1965, 43, 711–715. [Google Scholar] [CrossRef] [PubMed]
- Swerdlow, N.R.; Koob, G.F. Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striatopallido-thalamic function. Behav. Brain Sci. 1987, 10, 197–208. [Google Scholar] [CrossRef]
- Del Campo, N.; Chamberlain, S.R.; Sahakian, B.J.; Robbins, T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2011, 69, e145–e157. [Google Scholar] [CrossRef]
- Guo, J.Y.; Ragland, J.D.; Carter, C.S. Memory and cognition in schizophrenia. Mol. Psychiatry 2018, 24, 633–642. [Google Scholar] [CrossRef]
- Martinussen, R.; Hayden, J.; Hogg-Johnson, S.; Tannock, R. A meta-analysis of working memory impairments in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2005, 44, 377–384. [Google Scholar] [CrossRef]
- Aarsland, D.; Creese, B.; Politis, M.; Chaudhuri, K.R.; Ffytche, D.H.; Weintraub, D.; Ballard, C. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 2017, 13, 217–231. [Google Scholar] [CrossRef] [Green Version]
- Dalrymple-Alford, J.C.; Kalders, A.S.; Jones, R.D.; Watson, R.W. A central executive deficit in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1994, 57, 360–367. [Google Scholar] [CrossRef] [Green Version]
- Downes, J.J.; Roberts, A.C.; Sahakian, B.J.; Evenden, J.L.; Morris, R.G.; Robbins, T.W. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson’s disease: Evidence for a specific attentional dysfunction. Neuropsychologia 1989, 27, 1329–1343. [Google Scholar] [CrossRef]
- Boller, F.; Passafiume, D.; Keefe, N.C.; Rogers, K.; Morrow, L.; Kim, Y. Visuospatial impairment in Parkinson’s disease. Role of perceptual and motor factors. Arch. Neurol. 1984, 41, 485–490. [Google Scholar] [CrossRef]
- Warburton, J.W. Memory disturbance and the Parkinson syndrome. Br. J. Med. Psychol. 1967, 40, 169–171. [Google Scholar] [CrossRef] [PubMed]
- Wilson, R.S.; Kaszniak, A.W.; Klawans, H.L.; Garron, D.C. High speed memory scanning in parkinsonism. Cortex 1980, 16, 67–72. [Google Scholar] [CrossRef]
- Thabit, H.; Kyaw Tun, T.; McDermott, J.; Sreenan, S. Executive function and diabetes mellitus—A stone left unturned? Curr. Diabetes Rev. 2012, 8, 109–115. [Google Scholar] [CrossRef] [PubMed]
- Vincent, C.; Hall, P.A. Executive Function in Adults with Type 2 Diabetes: A Meta-Analytic Review. Psychosom. Med. 2015, 77, 631–642. [Google Scholar] [CrossRef]
- Liao, J.L.; Xiong, Z.Y.; Yang, Z.K. An association of cognitive impairment with diabetes and retinopathy in end stage renal disease patients under peritoneal dialysis. PLoS ONE 2017, 12, e0183965. [Google Scholar] [CrossRef] [Green Version]
- Sadanand, S.; Balachandar, R.; Bharath, S. Memory and executive functions in persons with type 2 diabetes: A meta-analysis. Diabetes Metab. Res. Rev. 2016, 32, 132–142. [Google Scholar] [CrossRef]
- Brück, A.; Portin, R.; Lindell, A.; Laihinen, A.; Bergman, J.; Haaparanta, M.; Solin, O.; Rinne, J.O. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci. Lett. 2001, 311, 81–84. [Google Scholar] [CrossRef]
- Brück, A.; Aalto, S.; Nurmi, E.; Bergman, J.; Rinne, J.O. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol. Aging 2005, 26, 891–898. [Google Scholar] [CrossRef] [PubMed]
- Sawamoto, N.; Piccini, P.; Hotton, G.; Pavese, N.; Thielemans, K.; Brooks, D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease. Brain 2008, 131 Pt 5, 1294–1302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jokinen, P.; Brück, A.; Aalto, S.; Forsback, S.; Parkkola, R.; Rinne, J.O. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat. Disord. 2009, 15, 88–93. [Google Scholar] [CrossRef]
- Lebowitz, J.J.; Khoshbouei, H. Heterogeneity of dopamine release sites in health and degeneration. Neurobiol. Dis. 2020, 134, 104633. [Google Scholar] [CrossRef]
- Seeman, P.; Bzowej, N.H.; Guan, H.C.; Bergeron, C.; Becker, L.E.; Reynolds, G.P.; Bird, E.D.; Riederer, P.; Jellinger, K.; Watanabe, S.; et al. Human brain dopamine receptors in children and aging adults. Synapse 1987, 1, 399–404. [Google Scholar] [CrossRef] [PubMed]
- Volkow, N.D.; Fowler, J.S.; Wang, G.J.; Logan, J.; Schlyer, D.; MacGregor, R.; Hitzemann, R.; Wolf, A.P. Decreased dopamine transporters with age in health human subjects. Ann. Neurol. 1994, 36, 237–239. [Google Scholar] [CrossRef]
- Frey, K.A.; Koeppe, R.A.; Kilbourn, M.R.; Vander Borght, T.M.; Albin, R.L.; Gilman, S.; Kuhl, D.E. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann. Neurol. 1996, 40, 873–884. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, K.; Ishii, K.; Oda, K.; Kawasaki, K.; Mizusawa, H.; Ishiwata, K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009, 63, 282–290. [Google Scholar] [CrossRef] [PubMed]
- Mozley, L.H.; Gur, R.C.; Mozley, P.D.; Gur, R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am. J. Psychiatry 2001, 158, 1492–1499. [Google Scholar] [CrossRef]
- Erixon-Lindroth, N.; Farde, L.; Wahlin, T.B.; Sovago, J.; Halldin, C.; Bäckman, L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 2005, 138, 1–12. [Google Scholar] [CrossRef]
- Bäckman, L.; Ginovart, N.; Dixon, R.A.; Wahlin, T.B.; Wahlin, A.; Halldin, C.; Farde, L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am. J. Psychiatry 2000, 157, 635–637. [Google Scholar] [CrossRef]
- Reeves, S.J.; Grasby, P.M.; Howard, R.J.; Bantick, R.A.; Asselin, M.C.; Mehta, M.A. A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. Neuroimage 2005, 28, 216–226. [Google Scholar] [CrossRef]
- Volkow, N.D.; Gur, R.C.; Wang, G.J.; Fowler, J.S.; Moberg, P.J.; Ding, Y.S.; Hitzemann, R.; Smith, G.; Logan, J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 1998, 155, 344–349. [Google Scholar] [CrossRef]
- Fowler, C.J.; Wiberg, A.; Oreland, L.; Marcusson, J.; Winblad, B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm. 1980, 49, 1–20. [Google Scholar] [CrossRef]
- Berry, A.S.; Shah, V.D.; Baker, S.L.; Vogel, J.W.; O’Neil, J.P.; Janabi, M.; Schwimmer, H.D.; Marks, S.M.; Jagust, W.J. Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility. J. Neurosci. 2016, 36, 12559–12569. [Google Scholar] [CrossRef]
- Juarez, E.J.; Castrellon, J.J.; Green, M.A.; Crawford, J.L.; Seaman, K.L.; Smith, C.T.; Dang, L.C.; Matuskey, D.; Morris, E.D.; Cowan, R.L.; et al. Reproducibility of the correlative triad among aging, dopamine receptor availability, and cognition. Psychol. Aging 2019, 34, 921–932. [Google Scholar] [CrossRef]
- Nobili, A.; Latagliata, E.C.; Viscomi, M.T.; Cavallucci, V.; Cutuli, D.; Giacovazzo, G.; Krashia, P.; Rizzo, F.R.; Marino, R.; Federici, M.; et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nat. Commun. 2017, 8, 14727. [Google Scholar] [CrossRef] [PubMed]
- Pavăl, D. A Dopamine Hypothesis of Autism Spectrum Disorder. Dev. Neurosci. 2017, 39, 355–360. [Google Scholar] [CrossRef] [PubMed]
- Schwab, L.C.; Garas, S.N.; Drouin-Ouellet, J.; Mason, S.L.; Stott, S.R.; Barker, R.A. Dopamine and Huntington’s disease. Expert Rev. Neurother. 2015, 15, 445–458. [Google Scholar] [CrossRef]
- Phillips, A.G.; Ahn, S.; Floresco, S.B. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J. Neurosci. 2004, 24, 547–553. [Google Scholar] [CrossRef]
- Watanabe, M.; Kodama, T.; Hikosaka, K. Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J. Neurophysiol. 1997, 78, 2795–2798. [Google Scholar] [CrossRef]
- Yang, C.R.; Seamans, J.K. Dopamine D1 receptor actions in layers V–VI rat prefrontal cortex neurons in vitro: Modulation of dendritic-somatic signal integration. J. Neurosci. 1996, 16, 1922–1935. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simon, H.; Taghzouti, K.; Le Moal, M. Deficits in spatial-memory tasks following lesions of septal dopaminergic terminals in the rat. Behav. Brain Res. 1986, 19, 7–16. [Google Scholar] [CrossRef]
- Bubser, M.; Schmidt, W.J. 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav. Brain Res. 1990, 37, 157–168. [Google Scholar] [CrossRef]
- Brozoski, T.J.; Brown, R.M.; Rosvold, H.E.; Goldman, P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205, 929–932. [Google Scholar] [CrossRef] [PubMed]
- Mishkin, M. Effects of small frontal lesions on delayed alternation in monkeys. J. Neurophysiol. 1957, 20, 615–622. [Google Scholar] [CrossRef] [PubMed]
- Gross, C.G.; Weiskrantz, L. Evidence for dissociation of impairment on auditory discrimination and delayed response following lateral frontal lesions in monkeys. Exp. Neurol. 1962, 5, 453–476. [Google Scholar] [CrossRef] [PubMed]
- Cools, R.; Froböse, M.; Aarts, E.; Hofmans, L. Dopamine and the motivation of cognitive control. Handb. Clin. Neurol. 2019, 163, 123–143. [Google Scholar] [CrossRef]
- Arnsten, A.F.; Cai, J.X.; Murphy, B.L.; Goldman-Rakic, P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 1994, 116, 143–151. [Google Scholar] [CrossRef]
- Sawaguchi, T.; Goldman-Rakic, P.S. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science 1991, 251, 947–950. [Google Scholar] [CrossRef]
- Williams, G.V.; Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376, 572–575. [Google Scholar] [CrossRef]
- Zahrt, J.; Taylor, J.R.; Mathew, R.G.; Arnsten, A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 1997, 17, 8528–8535. [Google Scholar] [CrossRef] [Green Version]
- Arnsten, A.F. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn. Sci. 1998, 2, 436–447. [Google Scholar] [CrossRef]
- Luciana, M.; Depue, R.A.; Arbisi, P.; Leon, A. Facilitation of working memory in humans by a d2 dopamine receptor agonist. J. Cogn. Neurosci. 1992, 4, 58–68. [Google Scholar] [CrossRef]
- Kimberg, D.Y.; D’Esposito, M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 2003, 41, 1020–1027. [Google Scholar] [CrossRef]
- Cools, R.; D’Esposito, M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2011, 69, e113–e125. [Google Scholar] [CrossRef] [Green Version]
- Torstenson, R.; Hartvig, P.; Långström, B.; Bastami, S.; Antoni, G.; Tedroff, J. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 1998, 37, 989–995. [Google Scholar] [CrossRef]
- Marino, R.A.; Levy, R. Differential effects of D1 and D2 dopamine agonists on memory, motivation, learning and response time in non-human primates. Eur. J. Neurosci. 2019, 49, 199–214. [Google Scholar] [CrossRef] [PubMed]
- Stern, Y.; Tetrud, J.W.; Martin, W.R.; Kutner, S.J.; Langston, J.W. Cognitive change following MPTP exposure. Neurology 1990, 40, 261–264. [Google Scholar] [CrossRef] [PubMed]
- Da Cunha, C.; Angelucci, M.E.; Canteras, N.S.; Wonnacott, S.; Takahashi, R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson’s disease memory disabilities. Cell. Mol. Neurobiol. 2002, 22, 227–237. [Google Scholar] [CrossRef] [PubMed]
- Braga, R.; Kouzmine, I.; Canteras, N.S.; Da Cunha, C. Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp. Neurol. 2005, 192, 134–141. [Google Scholar] [CrossRef]
- Da Cunha, C.; Gevaerd, M.S.; Vital, M.A.; Miyoshi, E.; Andreatini, R.; Silveira, R.; Takahashi, R.N.; Canteras, N.S. Memory disruption in rats with nigral lesions induced by MPTP: A model for early Parkinson’s disease amnesia. Behav. Brain Res. 2001, 124, 9–18. [Google Scholar] [CrossRef]
- Tadaiesky, M.T.; Dombrowski, P.A.; Figueiredo, C.P.; Cargnin-Ferreira, E.; Da Cunha, C.; Takahashi, R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson’s disease. Neuroscience 2008, 156, 830–840. [Google Scholar] [CrossRef] [PubMed]
- Packard, M.G.; Cahill, L.; McGaugh, J.L. Amygdala modulation of hippocampal-dependent and caudate nucleus-dependent memory processes. Proc. Natl. Acad. Sci. USA 1994, 91, 8477–8481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Packard, M.G.; White, N.M. Dissociation of hippocampus and caudate nucleus memory systems by posttraining intracerebral injection of dopamine agonists. Behav. Neurosci. 1991, 105, 295–306. [Google Scholar] [CrossRef] [PubMed]
- Schneider, J.S.; Sun, Z.Q.; Roeltgen, D.P. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 1994, 663, 140–144. [Google Scholar] [CrossRef]
- Chung, S.J.; Yoo, H.S.; Oh, J.S.; Kim, J.S.; Ye, B.S.; Sohn, Y.H.; Lee, P.H. Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease. Parkinsonism Relat. Disord. 2018, 51, 43–48. [Google Scholar] [CrossRef]
- Granon, S.; Passetti, F.; Thomas, K.L.; Dalley, J.W.; Everitt, B.J.; Robbins, T.W. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J. Neurosci. 2000, 20, 1208–1215. [Google Scholar] [CrossRef]
- Nieoullon, A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67, 53–83. [Google Scholar] [CrossRef]
- Amalric, M.; Moukhles, H.; Nieoullon, A.; Daszuta, A. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur. J. Neurosci. 1995, 7, 972–980. [Google Scholar] [CrossRef]
- Volkow, N.D.; Wang, G.J.; Tomasi, D.; Kollins, S.H.; Wigal, T.L.; Newcorn, J.H.; Telang, F.W.; Fowler, J.S.; Logan, J.; Wong, C.T.; et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J. Neurosci. 2012, 32, 841–849. [Google Scholar] [CrossRef] [Green Version]
- Turle-Lorenzo, N.; Maurin, B.; Puma, C.; Chezaubernard, C.; Morain, P.; Baunez, C.; Nieoullon, A.; Amalric, M. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: Relevance for Parkinson’s disease. J. Pharmacol. Exp. Ther. 2006, 319, 914–923. [Google Scholar] [CrossRef] [Green Version]
- Courtière, A.; Hardouin, J.; Goujon, A.; Vidal, F.; Hasbroucq, T. Selective effects of low-dose dopamine D1 and D2 receptor antagonists on rat information processing. Behav. Pharmacol. 2003, 14, 589–598. [Google Scholar] [CrossRef] [PubMed]
- Passetti, F.; Levita, L.; Robbins, T.W. Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav. Brain Res. 2003, 138, 59–69. [Google Scholar] [CrossRef]
- Kempadoo, K.A.; Mosharov, E.V.; Choi, S.J.; Sulzer, D.; Kandel, E.R. Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory. Proc. Natl. Acad. Sci. USA 2016, 113, 14835–14840. [Google Scholar] [CrossRef] [Green Version]
- Holmboe, K.; Nemoda, Z.; Fearon, R.M.; Csibra, G.; Sasvari-Szekely, M.; Johnson, M.H. Polymorphisms in dopamine system genes are associated with individual differences in attention in infancy. Dev. Psychol. 2010, 46, 404–416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malhotra, A.K.; Kestler, L.J.; Mazzanti, C.; Bates, J.A.; Goldberg, T.; Goldman, D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 2002, 159, 652–654. [Google Scholar] [CrossRef]
- Blasi, G.; Mattay, V.S.; Bertolino, A.; Elvevåg, B.; Callicott, J.H.; Das, S.; Kolachana, B.S.; Egan, M.F.; Goldberg, T.E.; Weinberger, D.R. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J. Neurosci. 2005, 25, 5038–5045. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Bertolino, A.; Fazio, L.; Blasi, G.; Rampino, A.; Romano, R.; Lee, M.L.; Xiao, T.; Papp, A.; Wang, D.; et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl. Acad. Sci. USA 2007, 104, 20552–20557. [Google Scholar] [CrossRef] [Green Version]
- Wiłkość, M.; Hauser, J.; Tomaszewska, M.; Dmitrzak-Weglarz, M.; Skibińska, M.; Szczepankiewicz, A.; Borkowska, A. Influence of dopaminergic and serotoninergic genes on working memory in healthy subjects. Acta Neurobiol. Exp. 2010, 70, 86–94. [Google Scholar]
- Smith, C.T.; Wallace, D.L.; Dang, L.C.; Aarts, E.; Jagust, W.J.; D’Esposito, M.; Boettiger, C.A. Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults. J. Neurophysiol. 2016, 115, 1146–1156. [Google Scholar] [CrossRef]
- Mehta, M.A.; Manes, F.F.; Magnolfi, G.; Sahakian, B.J.; Robbins, T.W. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology 2004, 176, 331–342. [Google Scholar] [CrossRef]
- Eagle, D.M.; Robbins, T.W. Inhibitory control in rats performing a stop-signal reaction-time task: Effects of lesions of the medial striatum and d-amphetamine. Behav. Neurosci. 2003, 117, 1302–1317. [Google Scholar] [CrossRef]
- Eban-Rothschild, A.; Rothschild, G.; Giardino, W.J.; Jones, J.R.; de Lecea, L. VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. Nat. Neurosci. 2016, 19, 1356–1366. [Google Scholar] [CrossRef] [PubMed]
- Shpakov, A.O.; Derkach, K.V.; Berstein, L.M. Brain signaling systems in the Type 2 diabetes and metabolic syndrome: Promising target to treat and prevent these diseases. Future Sci. OA 2015, 1, FSO25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de la Monte, S.M.; Tong, M.; Nguyen, V.; Setshedi, M.; Longato, L.; Wands, J.R. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J. Alzheimers Dis. 2010, 21, 967–984. [Google Scholar] [CrossRef] [Green Version]
- Baranov, V.G.; Propp, M.V.; Sokoloverova, I.M.; Savchenko, O.N.; Onegova, R.F. Dopamine, noradrenaline and serotonin content in various parts of the hypothalamus in alloxan diabetes. Probl. Endokrinol. 1980, 26, 43–48. [Google Scholar]
- Lacković, Z.; Salković, M. Streptozotocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. Life Sci. 1990, 46, 49–54. [Google Scholar] [CrossRef]
- Lacković, Z.; Salković, M.; Kuci, Z.; Relja, M. Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J. Neurochem. 1990, 54, 143–147. [Google Scholar] [CrossRef]
- Ezzeldin, E.; Souror, W.A.; El-Nahhas, T.; Soudi, A.N.; Shahat, A.A. Biochemical and neurotransmitters changes associated with tramadol in streptozotocin-induced diabetes in rats. BioMed Res. Int. 2014, 2014, 238780. [Google Scholar] [CrossRef]
- Rowland, N.E.; Bellush, L.L. Diabetes mellitus: Stress, neurochemistry and behavior. Neurosci. Biobehav. Rev. 1989, 13, 199–206. [Google Scholar] [CrossRef]
- Verberne, A.J.; Korim, W.S.; Sabetghadam, A.; Llewellyn-Smith, I.J. Adrenaline: Insights into its metabolic roles in hypoglycaemia and diabetes. Br. J. Pharmacol. 2016, 173, 1425–1437. [Google Scholar] [CrossRef] [Green Version]
- Babić Leko, M.; Hof, P.R.; Šimić, G. Alterations and interactions of subcortical modulatory systems in Alzheimer’s disease. Prog. Brain Res. 2021, 261, 379–421. [Google Scholar] [CrossRef] [PubMed]
- Kloiber, S.; Kohli, M.A.; Brueckl, T.; Ripke, S.; Ising, M.; Uhr, M.; Menke, A.; Unschuld, P.G.; Horstmann, S.; Salyakina, D.; et al. Variations in tryptophan hydroxylase 2 linked to decreased serotonergic activity are associated with elevated risk for metabolic syndrome in depression. Mol. Psychiatry 2010, 15, 736–747. [Google Scholar] [CrossRef] [Green Version]
- Zhou, L.; Sutton, G.M.; Rochford, J.J.; Semple, R.K.; Lam, D.D.; Oksanen, L.J.; Thornton-Jones, Z.D.; Clifton, P.G.; Yueh, C.Y.; Evans, M.L.; et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007, 6, 398–405. [Google Scholar] [CrossRef] [Green Version]
- Goodnick, P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry 2001, 13, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Chu, P.C.; Lin, M.T.; Shian, L.R.; Leu, S.Y. Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 1986, 35, 481–485. [Google Scholar] [CrossRef]
- Abraham, P.M.; Paul, J.; Paulose, C.S. Down regulation of cerebellar serotonergic receptors in streptozotocin induced diabetic rats: Effect of pyridoxine and Aegle marmelose. Brain Res. Bull. 2010, 82, 87–94. [Google Scholar] [CrossRef]
- Sandrini, M.; Vitale, G.; Vergoni, A.V.; Ottani, A.; Bertolini, A. Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain. Life Sci. 1997, 60, 1393–1397. [Google Scholar] [CrossRef]
- Kino, M.; Yamato, T.; Aomine, M. Simultaneous measurement of nitric oxide, blood glucose, and monoamines in the hippocampus of diabetic rat: An in vivo microdialysis study. Neurochem. Int. 2004, 44, 65–73. [Google Scholar] [CrossRef]
- Yamato, T.; Misumi, Y.; Yamasaki, S.; Kino, M.; Aomine, M. Diabetes mellitus decreases hippocampal release of neurotransmitters: An in vivo microdialysis study of awake, freely moving rats. Diabetes Nutr. Metab. 2004, 17, 128–136. [Google Scholar]
- Ohtani, N.; Ohta, M.; Sugano, T. Microdialysis study of modification of hypothalamic neurotransmitters in streptozotocin-diabetic rats. J. Neurochem. 1997, 69, 1622–1628. [Google Scholar] [CrossRef]
- Fernstrom, J.D. Large neutral amino acids: Dietary effects on brain neurochemistry and function. Amino Acids. 2013, 45, 419–430. [Google Scholar] [CrossRef] [PubMed]
- Zemdegs, J.; Quesseveur, G.; Jarriault, D.; Pénicaud, L.; Fioramonti, X.; Guiard, B.P. High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice. Br. J. Pharmacol. 2016, 173, 2095–2110. [Google Scholar] [CrossRef] [PubMed]
- Jorgensen, K.D. Actions of fenfluramine on glucose uptake in vitro and in vivo. Acta Pharmacol. Toxicol. 1977, 40, 401–417. [Google Scholar] [CrossRef]
- Russell, J.C.; Dolphin, P.J.; Graham, S.E.; Amy, R.M.; Brindley, D.N. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetologia 1998, 41, 380–389. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arora, R.; Dryden, S.; McKibbin, P.E.; Williams, G. Acute dexfenfluramine administration normalizes glucose tolerance in rats with insulin-deficient diabetes. Eur. J. Clin. Investig. 1994, 24, 182–187. [Google Scholar] [CrossRef] [PubMed]
- Derkach, K.V.; Bondareva, V.M.; Chistyakova, O.V.; Berstein, L.M.; Shpakov, A.O. The Effect of Long-Term Intranasal Serotonin Treatment on Metabolic Parameters and Hormonal Signaling in Rats with High-Fat Diet/Low-Dose Streptozotocin-Induced Type 2 Diabetes. Int. J. Endocrinol. 2015, 2015, 245459. [Google Scholar] [CrossRef] [Green Version]
- Biskup, C.S.; Sánchez, C.L.; Arrant, A.; Van Swearingen, A.E.; Kuhn, C.; Zepf, F.D. Effects of acute tryptophan depletion on brain serotonin function and concentrations of dopamine and norepinephrine in C57BL/6J and BALB/cJ mice. PLoS ONE 2012, 7, e35916. [Google Scholar] [CrossRef]
- Jans, L.A.; Korte-Bouws, G.A.; Korte, S.M.; Blokland, A. The effects of acute tryptophan depletion on affective behaviour and cognition in Brown Norway and Sprague Dawley rats. J. Psychopharmacol. 2010, 24, 605–614. [Google Scholar] [CrossRef]
- Young, S.N.; Ervin, F.R.; Pihl, R.O.; Finn, P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology 1989, 98, 508–511. [Google Scholar] [CrossRef]
- Young, S.N.; Smith, S.E.; Pihl, R.O.; Ervin, F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 1985, 87, 173–177. [Google Scholar] [CrossRef] [PubMed]
- Riedel, W.J.; Klaassen, T.; Deutz, N.E.; van Someren, A.; van Praag, H.M. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999, 141, 362–369. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez, J.J.; Noristani, H.N.; Verkhratsky, A. The serotonergic system in ageing and Alzheimer’s disease. Prog. Neurobiol. 2012, 99, 15–41. [Google Scholar] [CrossRef] [PubMed]
- Whiley, L.; Chappell, K.E.; D’Hondt, E.; Lewis, M.R.; Jiménez, B.; Snowden, S.G.; Soininen, H.; Kłoszewska, I.; Mecocci, P.; Tsolaki, M.; et al. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease. Alzheimers Res. Ther. 2021, 13, 20. [Google Scholar] [CrossRef]
- Jenkins, T.A.; Nguyen, J.C.; Polglaze, K.E.; Bertrand, P.P. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients 2016, 8, 56. [Google Scholar] [CrossRef] [PubMed]
- Sukhov, I.B.; Chistyakova, O.V.; Shipilov, V.N.; Doilnitsyn, A.M.; Shpakov, A.O. Spatial memory and regulation of brain adenylyl cyclase by serotonin and dopamine in rat with streptozotocin diabetes. Ross. Fiziol. Zhurnal Im. IM Sechenova 2015, 101, 279–290. [Google Scholar]
- Pan, Y.; Gembom, E.; Peng, W.; Lesch, K.P.; Mossner, R.; Simantov, R. Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice. Brain Res. Dev. Brain Res. 2001, 126, 125–129. [Google Scholar] [CrossRef]
- Gardier, A.M.; Moratalla, R.; Cuéllar, B.; Sacerdote, M.; Guibert, B.; Lebrec, H.; Graybiel, A.M. Interaction between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons. J. Neurochem. 2000, 74, 1363–1373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rouillard, C.; Bovetto, S.; Gervais, J.; Richard, D. Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: Possible interaction between serotonin and dopamine. Brain Res. Mol. Brain Res. 1996, 37, 105–115. [Google Scholar] [CrossRef]
- Yadid, G.; Pacak, K.; Kopin, I.J.; Goldstein, D.S. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J. Pharmacol. Exp. Ther. 1994, 270, 1158–1165. [Google Scholar]
- Doherty, M.D.; Pickel, V.M. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 2000, 864, 176–185. [Google Scholar] [CrossRef]
- Nocjar, C.; Roth, B.L.; Pehek, E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002, 111, 163–176. [Google Scholar] [CrossRef]
- de Bartolomeis, A.; Fiore, G. Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: Implications for human behavior pathologies. Int. Rev. Neurobiol. 2004, 59, 221–254. [Google Scholar] [CrossRef] [PubMed]
- de Bartolomeis, A.; Buonaguro, E.F.; Iasevoli, F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: From receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology 2013, 225, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Ter Horst, K.W.; Lammers, N.M.; Trinko, R.; Opland, D.M.; Figee, M.; Ackermans, M.T.; Booij, J.; van den Munckhof, P.; Schuurman, P.R.; Fliers, E.; et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci. Transl. Med. 2018, 10, eaar3752. [Google Scholar] [CrossRef] [Green Version]
- Wang, G.J.; Volkow, N.D.; Logan, J.; Pappas, N.R.; Wong, C.T.; Zhu, W.; Netusil, N.; Fowler, J.S. Brain dopamine and obesity. Lancet 2001, 357, 354–357. [Google Scholar] [CrossRef]
- de Weijer, B.A.; van de Giessen, E.; van Amelsvoort, T.A.; Boot, E.; Braak, B.; Janssen, I.M.; van de Laar, A.; Fliers, E.; Serlie, M.J.; Booij, J. Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res. 2011, 1, 37. [Google Scholar] [CrossRef] [Green Version]
- García-Tornadú, I.; Ornstein, A.M.; Chamson-Reig, A.; Wheeler, M.B.; Hill, D.J.; Arany, E.; Rubinstein, M.; Becu-Villalobos, D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010, 151, 1441–1450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lacau-Mengido, I.M.; Mejía, M.E.; Díaz-Torga, G.S.; Gonzalez Iglesias, A.; Formía, N.; Libertun, C.; Becú-Villalobos, D. Endocrine studies in ivermectin-treated heifers from birth to puberty. J. Anim. Sci. 2000, 78, 817–824. [Google Scholar] [CrossRef]
- Díaz-Torga, G.S.; Mejia, M.E.; González-Iglesias, A.; Formia, N.; Becú-Villalobos, D.; Lacau-Mengido, I.M. Metabolic cues for puberty onset in free grazing Holstein heifers naturally infected with nematodes. Theriogenology 2001, 56, 111–122. [Google Scholar] [CrossRef]
- Joseph, J.W.; Koshkin, V.; Saleh, M.C.; Sivitz, W.I.; Zhang, C.Y.; Lowell, B.B.; Chan, C.B.; Wheeler, M.B. Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 2004, 279, 51049–51056. [Google Scholar] [CrossRef] [Green Version]
- Tarricone, I.; Casoria, M.; Gozzi, B.F.; Grieco, D.; Menchetti, M.; Serretti, A.; Ujkaj, M.; Pastorelli, F.; Berardi, D. Metabolic risk factor profile associated with use of second generation antipsychotics: A cross sectional study in a Community Mental Health Centre. BMC Psychiatry 2006, 6, 11. [Google Scholar] [CrossRef] [Green Version]
- Ballon, J.S.; Pajvani, U.; Freyberg, Z.; Leibel, R.L.; Lieberman, J.A. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol. Metab. 2014, 25, 593–600. [Google Scholar] [CrossRef]
- Anitha, M.; Abraham, P.M.; Paulose, C.S. Striatal dopamine receptors modulate the expression of insulin receptor, IGF-1 and GLUT-3 in diabetic rats: Effect of pyridoxine treatment. Eur. J. Pharmacol. 2012, 696, 54–61. [Google Scholar] [CrossRef]
- Pérez-Taboada, I.; Alberquilla, S.; Martín, E.D.; Anand, R.; Vietti-Michelina, S.; Tebeka, N.N.; Cantley, J.; Cragg, S.J.; Moratalla, R.; Vallejo, M. Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice. Mov. Disord. 2020, 35, 1636–1648. [Google Scholar] [CrossRef]
- Mielke, J.G.; Wang, Y.T. Insulin exerts neuroprotection by counteracting the decrease in cell-surface GABA receptors following oxygen-glucose deprivation in cultured cortical neurons. J. Neurochem. 2005, 92, 103–113. [Google Scholar] [CrossRef]
- Ramalingam, M.; Kim, S.J. The role of insulin against hydrogen peroxide-induced oxidative damages in differentiated SH-SY5Y cells. J. Recept. Signal Transduct. 2014, 34, 212–220. [Google Scholar] [CrossRef]
- Pang, Y.; Lin, S.; Wright, C.; Shen, J.; Carter, K.; Bhatt, A.; Fan, L.W. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 2016, 318, 157–165. [Google Scholar] [CrossRef] [Green Version]
- Carvelli, L.; Morón, J.A.; Kahlig, K.M.; Ferrer, J.V.; Sen, N.; Lechleiter, J.D.; Leeb-Lundberg, L.M.; Merrill, G.; Lafer, E.M.; Ballou, L.M.; et al. PI 3-kinase regulation of dopamine uptake. J. Neurochem. 2002, 81, 859–869. [Google Scholar] [CrossRef]
- Garcia, B.G.; Wei, Y.; Moron, J.A.; Lin, R.Z.; Javitch, J.A.; Galli, A. Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol. Pharmacol. 2005, 68, 102–109. [Google Scholar] [CrossRef] [Green Version]
- Owens, W.A.; Sevak, R.J.; Galici, R.; Chang, X.; Javors, M.A.; Galli, A.; France, C.P.; Daws, L.C. Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J. Neurochem. 2005, 94, 1402–1410. [Google Scholar] [CrossRef]
- Wei, Y.; Williams, J.M.; Dipace, C.; Sung, U.; Javitch, J.A.; Galli, A.; Saunders, C. Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a Ca2+/calmodulin-dependent kinase II-dependent mechanism. Mol. Pharmacol. 2007, 71, 835–842. [Google Scholar] [CrossRef] [Green Version]
- Könner, A.C.; Hess, S.; Tovar, S.; Mesaros, A.; Sánchez-Lasheras, C.; Evers, N.; Verhagen, L.A.; Brönneke, H.S.; Kleinridders, A.; Hampel, B.; et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab. 2011, 13, 720–728. [Google Scholar] [CrossRef] [Green Version]
- Hong, C.T.; Chen, K.Y.; Wang, W.; Chiu, J.Y.; Wu, D.; Chao, T.Y.; Hu, C.J.; Chau, K.D.; Bamodu, O.A. Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling. Cells 2020, 9, 740. [Google Scholar] [CrossRef] [Green Version]
- Kleinridders, A.; Cai, W.; Cappellucci, L.; Ghazarian, A.; Collins, W.R.; Vienberg, S.G.; Pothos, E.N.; Kahn, C.R. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. USA 2015, 112, 3463–3468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Potter, G.M.; Moshirfar, A.; Castonguay, T.W. Insulin affects dopamine overflow in the nucleus accumbens and the striatum. Physiol. Behav. 1999, 65, 811–816. [Google Scholar] [CrossRef]
- Fiory, F.; Mirra, P.; Nigro, C.; Pignalosa, F.C.; Zatterale, F.; Ulianich, L.; Prevete, N.; Formisano, P.; Beguinot, F.; Miele, C. Role of the HIF-1α/Nur77 axis in the regulation of the tyrosine hydroxylase expression by insulin in PC12 cells. J. Cell. Physiol. 2018, 234, 11861–11870. [Google Scholar] [CrossRef]
- Patterson, T.A.; Brot, M.D.; Zavosh, A.; Schenk, J.O.; Szot, P.; Figlewicz, D.P. Food deprivation decreases mRNA and activity of the rat dopamine transporter. Neuroendocrinology 1998, 68, 11–20. [Google Scholar] [CrossRef]
- Speed, N.K.; Matthies, H.J.; Kennedy, J.P.; Vaughan, R.A.; Javitch, J.A.; Russo, S.J.; Lindsley, C.W.; Niswender, K.; Galli, A. Akt-dependent and isoform-specific regulation of dopamine transporter cell surface expression. ACS Chem. Neurosci. 2010, 1, 476–481. [Google Scholar] [CrossRef] [Green Version]
- Bournival, J.; Francoeur, M.A.; Renaud, J.; Martinoli, M.G. Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation, nitrosative stress, and apoptosis. Rejuvenation Res. 2012, 15, 322–333. [Google Scholar] [CrossRef]
- Renaud, J.; Bournival, J.; Zottig, X.; Martinoli, M.G. Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: Effect on p53 and GRP75 localization. Neurotox Res. 2014, 25, 110–123. [Google Scholar] [CrossRef] [Green Version]
- Su, C.J.; Shen, Z.; Cui, R.X.; Huang, Y.; Xu, D.L.; Zhao, F.L.; Pan, J.; Shi, A.M.; Liu, T.; Yu, Y.L. Thioredoxin-Interacting Protein (TXNIP) Regulates Parkin/PINK1-mediated Mitophagy in Dopaminergic Neurons Under High-glucose Conditions: Implications for Molecular Links Between Parkinson’s Disease and Diabetes. Neurosci. Bull. 2020, 36, 346–358. [Google Scholar] [CrossRef]
- Koshimura, K.; Tanaka, J.; Murakami, Y.; Kato, Y. Effect of high concentration of glucose on dopamine release from pheochromocytoma-12 cells. Metabolism 2003, 52, 922–926. [Google Scholar] [CrossRef]
- Umhau, J.C.; Petrulis, S.G.; Diaz, R.; Rawlings, R.; George, D.T. Blood glucose is correlated with cerebrospinal fluid neurotransmitter metabolites. Neuroendocrinology 2003, 78, 339–343. [Google Scholar] [CrossRef] [PubMed]
- Levin, B.E. Glucose-regulated dopamine release from substantia nigra neurons. Brain Res. 2000, 874, 158–164. [Google Scholar] [CrossRef]
- Pinkas, A.; Lawes, M.; Aschner, M. System-specific neurodegeneration following glucotoxicity in the C. elegans model. Neurotoxicology 2018, 68, 88–90. [Google Scholar] [CrossRef] [PubMed]
- Ramakrishnan, R.; Kempuraj, D.; Prabhakaran, K.; Jayakumar, A.R.; Devi, R.S.; Suthanthirarajan, N.; Namasivayam, A. A short-term diabetes induced changes of catecholamines and p38-MAPK in discrete areas of rat brain. Life Sci. 2005, 77, 1825–1835. [Google Scholar] [CrossRef]
- Robinson, R.; Krishnakumar, A.; Paulose, C.S. Enhanced dopamine D1 and D2 receptor gene expression in the hippocampus of hypoglycaemic and diabetic rats. Cell. Mol. Neurobiol. 2009, 29, 365–372. [Google Scholar] [CrossRef]
- Gallego, M.; Setién, R.; Izquierdo, M.J.; Casis, O.; Casis, E. Diabetes-induced biochemical changes in central and peripheral catecholaminergic systems. Physiol. Res. 2003, 52, 735–741. [Google Scholar]
- Renaud, J.; Bassareo, V.; Beaulieu, J.; Pinna, A.; Schlich, M.; Lavoie, C.; Murtas, D.; Simola, N.; Martinoli, M.G. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: Preferential degeneration of the nigrostriatal motor pathway. Neurobiol. Aging 2018, 69, 117–128. [Google Scholar] [CrossRef]
- Kwok, R.P.; Juorio, A.V. Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration. Neuroendocrinology 1986, 43, 590–596. [Google Scholar] [CrossRef]
- Bitar, M.; Koulu, M.; Rapoport, S.I.; Linnoila, M. Diabetes-induced alteration in brain monoamine metabolism in rats. J. Pharmacol. Exp. Ther. 1986, 236, 432–437. [Google Scholar]
- Figlewicz, D.P.; Brot, M.D.; McCall, A.L.; Szot, P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study. Brain Res. 1996, 736, 54–60. [Google Scholar] [CrossRef]
- Glanville, N.T.; Anderson, G.H. Hypothalamic catecholamine metabolism in diabetic rats: The effect of insulin deficiency and meal ingestion. J. Neurochem. 1986, 46, 753–759. [Google Scholar] [CrossRef]
- Nascimento, P.S.; Lovatel, G.A.; Barbosa, S.; Ilha, J.; Centenaro, L.A.; Malysz, T.; Xavier, L.L.; Schaan, B.D.; Achaval, M. Treadmill training improves motor skills and increases tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta in diabetic rats. Brain Res. 2011, 1382, 173–180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kono, T.; Takada, M. Dopamine depletion in nigrostriatal neurons in the genetically diabetic rat. Brain Res. 1994, 634, 155–158. [Google Scholar] [CrossRef]
- Azevedo, M.; Fernandes, F.; Lisboa, P.; Manso, C. Platelet monoamine oxidase activity in diabetics. Acta Med. Port. 1980, 2, 369–376. [Google Scholar] [PubMed]
- Xiu, L.; Lin, M.; Liu, W.; Kong, D.; Liu, Z.; Zhang, Y.; Ouyang, P.; Liang, Y.; Zhong, S.; Chen, C.; et al. Association of DRD3, COMT, and SLC6A4 Gene Polymorphisms with Type 2 Diabetes in Southern Chinese: A Hospital-Based Case-Control Study. Diabetes Technol. Ther. 2015, 17, 580–586. [Google Scholar] [CrossRef]
- Kring, S.I.; Werge, T.; Holst, C.; Toubro, S.; Astrup, A.; Hansen, T.; Pedersen, O.; Sørensen, T.I. Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS ONE 2009, 4, e6696. [Google Scholar] [CrossRef]
- Xiu, L.; Liu, W.; Zhou, S.; Lin, M.; Ouyang, P.; Qin, J.; Zhao, X.; Kong, D.; Rao, S.; Ding, Y. Study on the association between catechol-O-methyltransferase gene polymorphisms and type 2 diabetes mellitus. Zhonghua Liu Xing Bing Xue Za Zhi 2014, 35, 190–194. [Google Scholar]
- Pagano, G.; Polychronis, S.; Wilson, H.; Giordano, B.; Ferrara, N.; Niccolini, F.; Politis, M. Diabetes mellitus and Parkinson disease. Neurology 2018, 90, e1654–e1662. [Google Scholar] [CrossRef]
- Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615–1625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, H.; Wu, J.; Jin, Z.; Yan, L.J. Protein Modifications as Manifestations of Hyperglycemic Glucotoxicity in Diabetes and Its Complications. Biochem. Insights 2016, 9, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nigro, C.; Leone, A.; Raciti, G.A.; Longo, M.; Mirra, P.; Formisano, P.; Beguinot, F.; Miele, C. Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage. Int. J. Mol. Sci. 2017, 18, 188. [Google Scholar] [CrossRef] [Green Version]
- van Sloten, T.T. Vascular dysfunction: At the heart of cardiovascular disease, cognitive impairment and depressive symptoms. Artery Res. 2017, 19, 18–23. [Google Scholar] [CrossRef] [Green Version]
- Nigro, C.; Leone, A.; Fiory, F.; Prevenzano, I.; Nicolò, A.; Mirra, P.; Beguinot, F.; Miele, C. Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging. Cells 2019, 8, 749. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fiory, F.; Lombardi, A.; Miele, C.; Giudicelli, J.; Beguinot, F.; Van Obberghen, E. Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 2011, 54, 2941–2952. [Google Scholar] [CrossRef] [Green Version]
- Riboulet-Chavey, A.; Pierron, A.; Durand, I.; Murdaca, J.; Giudicelli, J.; Van Obberghen, E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 2006, 55, 1289–1299. [Google Scholar] [CrossRef] [Green Version]
- Nigro, C.; Raciti, G.A.; Leone, A.; Fleming, T.H.; Longo, M.; Prevenzano, I.; Fiory, F.; Mirra, P.; D’Esposito, V.; Ulianich, L.; et al. Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia 2014, 57, 1485–1494. [Google Scholar] [CrossRef]
- Mirra, P.; Nigro, C.; Prevenzano, I.; Procopio, T.; Leone, A.; Raciti, G.A.; Andreozzi, F.; Longo, M.; Fiory, F.; Beguinot, F.; et al. The role of miR-190a in methylglyoxal-induced insulin resistance in endothelial cells. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 440–449. [Google Scholar] [CrossRef]
- Nigro, C.; Mirra, P.; Prevenzano, I.; Leone, A.; Fiory, F.; Longo, M.; Cabaro, S.; Oriente, F.; Beguinot, F.; Miele, C. miR-214-Dependent Increase of PHLPP2 Levels Mediates the Impairment of Insulin-Stimulated Akt Activation in Mouse Aortic Endothelial Cells Exposed to Methylglyoxal. Int. J. Mol. Sci. 2018, 19, 522. [Google Scholar] [CrossRef] [Green Version]
- Nigro, C.; Leone, A.; Longo, M.; Prevenzano, I.; Fleming, T.H.; Nicolò, A.; Parrillo, L.; Spinelli, R.; Formisano, P.; Nawroth, P.P.; et al. Methylglyoxal accumulation de-regulates HoxA5 expression, thereby impairing angiogenesis in glyoxalase 1 knock-down mouse aortic endothelial cells. Biochim. Biophys. Acta Mol. Basis Dis. 2019, 1865, 73–85. [Google Scholar] [CrossRef]
- Kikuchi, S.; Shinpo, K.; Moriwaka, F.; Makita, Z.; Miyata, T.; Tashiro, K. Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: Synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J. Neurosci. Res. 1999, 57, 280–289. [Google Scholar] [CrossRef]
- Beeri, M.S.; Moshier, E.; Schmeidler, J.; Godbold, J.; Uribarri, J.; Reddy, S.; Sano, M.; Grossman, H.T.; Cai, W.; Vlassara, H.; et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 2011, 132, 583–587. [Google Scholar] [CrossRef]
- Yaffe, K.; Lindquist, K.; Schwartz, A.V.; Vitartas, C.; Vittinghoff, E.; Satterfield, S.; Simonsick, E.M.; Launer, L.; Rosano, C.; Cauley, J.A.; et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011, 77, 1351–1356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Loreto, S.; Zimmitti, V.; Sebastiani, P.; Cervelli, C.; Falone, S.; Amicarelli, F. Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int. J. Biochem. Cell Biol. 2008, 40, 245–257. [Google Scholar] [CrossRef]
- Heimfarth, L.; Loureiro, S.O.; Pierozan, P.; de Lima, B.O.; Reis, K.P.; Torres, E.B.; Pessoa-Pureur, R. Methylglyoxal-induced cytotoxicity in neonatal rat brain: A role for oxidative stress and MAP kinases. Metab. Brain Dis. 2013, 28, 429–438. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Wang, F.; Chen, W.; Chen, Y.; Wang, N.; von Maltzan, K. Possible link between the cognitive dysfunction associated with diabetes mellitus and the neurotoxicity of methylglyoxal. Brain Res. 2012, 1469, 82–91. [Google Scholar] [CrossRef] [PubMed]
- Hansen, F.; Pandolfo, P.; Galland, F.; Torres, F.V.; Dutra, M.F.; Batassini, C.; Guerra, M.C.; Leite, M.C.; Gonçalves, C.A. Methylglyoxal can mediate behavioral and neurochemical alterations in rat brain. Physiol. Behav. 2016, 164 Pt A, 93–101. [Google Scholar] [CrossRef]
- Lissner, L.J.; Rodrigues, L.; Wartchow, K.M.; Borba, E.; Bobermin, L.D.; Fontella, F.U.; Hansen, F.; Quincozes-Santos, A.; Souza, D.O.G.; Gonçalves, C.A. Short-Term Alterations in Behavior and Astroglial Function after Intracerebroventricular Infusion of Methylglyoxal in Rats. Neurochem. Res. 2021, 46, 183–196. [Google Scholar] [CrossRef]
- Akhter, F.; Chen, D.; Akhter, A.; Sosunov, A.A.; Chen, A.; McKhann, G.M.; Yan, S.F.; Yan, S.S. High Dietary Advanced Glycation End Products Impair Mitochondrial and Cognitive Function. J. Alzheimers Dis. 2020, 76, 165–178. [Google Scholar] [CrossRef]
- Smith, M.A.; Rudnicka-Nawrot, M.; Richey, P.L.; Praprotnik, D.; Mulvihill, P.; Miller, C.A.; Sayre, L.M.; Perry, G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer’s disease. J. Neurochem. 1995, 64, 2660–2666. [Google Scholar] [CrossRef]
- Vicente Miranda, H.; El-Agnaf, O.M.; Outeiro, T.F. Glycation in Parkinson’s disease and Alzheimer’s disease. Mov. Disord. 2016, 31, 782–790. [Google Scholar] [CrossRef] [PubMed]
- Haddad, M.; Perrotte, M.; Khedher, M.R.B.; Demongin, C.; Lepage, A.; Fülöp, T.; Ramassamy, C. Methylglyoxal and Glyoxal as Potential Peripheral Markers for MCI Diagnosis and Their Effects on the Expression of Neurotrophic, Inflammatory and Neurodegenerative Factors in Neurons and in Neuronal Derived-Extracellular Vesicles. Int. J. Mol. Sci. 2019, 20, 4906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- West, R.K.; Moshier, E.; Lubitz, I.; Schmeidler, J.; Godbold, J.; Cai, W.; Uribarri, J.; Vlassara, H.; Silverman, J.M.; Beeri, M.S. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech. Ageing Dev. 2014, 140, 10–12. [Google Scholar] [CrossRef] [Green Version]
- Srikanth, V.; Westcott, B.; Forbes, J.; Phan, T.G.; Beare, R.; Venn, A.; Pearson, S.; Greenaway, T.; Parameswaran, V.; Münch, G. Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A Biol. Sci. Med. Sci. 2013, 68, 68–73. [Google Scholar] [CrossRef] [Green Version]
- Song, D.W.; Xin, N.; Xie, B.J.; Li, Y.J.; Meng, L.Y.; Li, H.M.; Schläppi, M.; Deng, Y.L. Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. Int. J. Mol. Med. 2014, 33, 736–742. [Google Scholar] [CrossRef] [Green Version]
- Deng, Y.; Zhang, Y.; Li, Y.; Xiao, S.; Song, D.; Qing, H.; Li, Q.; Rajput, A.H. Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J. Neural Transm. 2012, 119, 435–441. [Google Scholar] [CrossRef]
- Xie, B.; Lin, F.; Ullah, K.; Peng, L.; Ding, W.; Dai, R.; Qing, H.; Deng, Y. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson’s disease. Biochem. Biophys. Res. Commun. 2015, 459, 361–366. [Google Scholar] [CrossRef] [PubMed]
- Farrer, M.; Kachergus, J.; Forno, L.; Lincoln, S.; Wang, D.S.; Hulihan, M.; Maraganore, D.; Gwinn-Hardy, K.; Wszolek, Z.; Dickson, D.; et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55, 174–179. [Google Scholar] [CrossRef]
- Sharma, N.; Rao, S.P.; Kalivendi, S.V. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson’s disease. Free Radic. Biol. Med. 2019, 135, 28–37. [Google Scholar] [CrossRef]
- de Almeida, G.R.L.; Szczepanik, J.C.; Selhorst, I.; Schmitz, A.E.; Dos Santos, B.; Cunha, M.P.; Heinrich, I.A.; de Paula, G.C.; De Bem, A.F.; Leal, R.B.; et al. Methylglyoxal-Mediated Dopamine Depletion, Working Memory Deficit, and Depression-Like Behavior Are Prevented by a Dopamine/Noradrenaline Reuptake Inhibitor. Mol. Neurobiol. 2021, 58, 735–749. [Google Scholar] [CrossRef]
- Szczepanik, J.C.; de Almeida, G.R.L.; Cunha, M.P.; Dafre, A.L. Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice. Neurochem. Res. 2020, 45, 354–370. [Google Scholar] [CrossRef] [PubMed]
- Xie, B.; Lin, F.; Peng, L.; Ullah, K.; Wu, H.; Qing, H.; Deng, Y. Methylglyoxal increases dopamine level and leads to oxidative stress in SH-SY5Y cells. Acta Biochim. Biophys. Sin. 2014, 46, 950–956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simpson, I.A.; Carruthers, A.; Vannucci, S.J. Supply and demand in cerebral energy metabolism: The role of nutrient transporters. J. Cereb. Blood Flow Metab. 2007, 27, 1766–1791. [Google Scholar] [CrossRef]
- Sergi, D.; Renaud, J.; Simola, N.; Martinoli, M.G. Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences. Front. Aging Neurosci. 2019, 11, 302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pignalosa, F.C.; Desiderio, A.; Mirra, P.; Nigro, C.; Perruolo, G.; Ulianich, L.; Formisano, P.; Beguinot, F.; Miele, C.; Napoli, R.; et al. Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction. Int. J. Mol. Sci. 2021, 22, 12366. https://doi.org/10.3390/ijms222212366
Pignalosa FC, Desiderio A, Mirra P, Nigro C, Perruolo G, Ulianich L, Formisano P, Beguinot F, Miele C, Napoli R, et al. Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction. International Journal of Molecular Sciences. 2021; 22(22):12366. https://doi.org/10.3390/ijms222212366
Chicago/Turabian StylePignalosa, Francesca Chiara, Antonella Desiderio, Paola Mirra, Cecilia Nigro, Giuseppe Perruolo, Luca Ulianich, Pietro Formisano, Francesco Beguinot, Claudia Miele, Raffaele Napoli, and et al. 2021. "Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction" International Journal of Molecular Sciences 22, no. 22: 12366. https://doi.org/10.3390/ijms222212366